摘要
2017年以来,我国医疗保障部门完成了4次医保目录的调整工作。由于调整药品上市证据质量较低,药物经济学评估结论在我国医保准入决策中的可参考性较弱。随着愈来愈多的全球同步上市新药将在我国上市,如何提高药物经济学在医保准入决策中的利用度成为社会关注的重要问题。本文根据药物经济学评价中参照药物的选择机制,从选择标准、选择方式和成本测量3个方面进行分析,提出优化建议,以推进医保目录动态调整机制科学化。
Since 2017,the National Healthcare Security Administration has adjusted the national reimbursement drug list(NRDL)for four times.Due to the long marketing cycle and low quality of evidence for adjusted drugs,the reference of pharmacoeconomic evaluation results in reimbursement decision-making was relatively weak.With an increasing number of globally new innovative medicines about to be firstly launched in China,how to improving utilization of pharmacoeconomic evaluation results in reimbursement decision-making will be an important issue of social concern.This article focused on the mechanism of selecting the comparator in pharmacoeconomic analysis,analyzed from selection criteria,selection methods and cost measurement,and put forward optimization suggestions to put the NRDL dynamic adjustment mechanism on a more scientific basis.
作者
李伟
丁锦希
施慧
李轶
LI Wei;DING Jinxi;SHI Hui;LI Yi(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,Jiangsu Province,China;Pharmaceutical Market Access Policy Research Center,China Pharmaceutical University,Nanjing 211198,Jiangsu Province,China)
出处
《世界临床药物》
CAS
2021年第1期11-15,共5页
World Clinical Drug
基金
中国药科大学“双一流”学科创新团队建设项目(CPU2018GY4)
江苏省教育厅2019年度高校哲学社会科学研究一般项目(2019SJA0063)。
